MRSA more virulent in space
25 February 2013
Research on board the International Space Station (ISS) has found
that spaceflight culture increases the disease-causing potential
(virulence) of the foodborne pathogen Salmonella.
Cheryl Nickerson, a microbiologist at Arizona State University's
Biodesign Institute, is using the ISS platform to pursue new
research into the effects of microgravity on disease-causing
organisms. She presented her research findings and charted the
course for future investigations aboard the ISS at the 2013 annual
meeting of the American Association for the Advancement of Science
in Boston earlier this month.
"One important focus of my research is to use the microgravity
environment of spaceflight as an innovative biomedical research
platform," she said. "We seek to unveil novel cellular and molecular
mechanisms related to infectious disease progression that cannot be
observed here on Earth, and to translate our findings to novel
strategies for treatment and prevention."
The International Space Station, where research
has shown MRSA is more virulent in weightless conditions
During an earlier series of NASA space shuttle and ground-based
experiments, Nickerson and her team made a startling discovery.
Spaceflight culture increased the disease-causing potential
(virulence) of the foodborne pathogen Salmonella, yet many of the
genes known to be important for its virulence were not turned on and
off as expected when this organism is grown on Earth. Understanding
how this switching is regulated may be useful for designing targeted
strategies to prevent infection.
For NASA, Nickerson's findings were revelatory, given their
implications for the health of astronauts on extended spaceflight
missions. Already faced with the potential for compromised immunity
induced by the rigors of space travel, astronauts may have to
further contend with the threat of disease-causing microbes with
amped-up infectious abilities. A more thorough understanding of
infectious processes and host responses under these conditions is
therefore vital for the design of therapeutics and other methods of
limiting vulnerability for those on space missions.
The story however, doesn't end there. Further research by
Nickerson's team pointed to important implications for the
understanding of health and disease on Earth. Her team, including
NASA scientists, showed that one of the central factors affecting
the behaviour of pathogenic cells is the physical force produced by
the movement of fluid over a bacterial cell's sensitive surface.
This property, known as fluid shear, helps modulate a broad range of
cell behaviours, provoking changes in cell morphology, virulence,
and global alterations in gene expression, in pathogens like
Salmonella.
"There are conditions that are encountered by pathogens during
the infection process in the human body that are relevant to
conditions that these same organisms experience when cultured in
spaceflight. By studying the effect of spaceflight on the
disease-causing potential of major pathogens like Salmonella, we may
be able to provide insight into infectious disease mechanisms that
cannot be attained using traditional experimental approaches on
Earth, where gravity can mask key cellular responses," says
Nickerson
Nickerson's spaceflight studies also pinpointed an evolutionarily
conserved protein — called Hfq — which appears to act as a global
regulator of gene responses to spaceflight conditions. Further
research by her team established that Hfq is a central mediator in
the spaceflight-induced responses of other bacterial pathogens,
including Pseudomonas aeruginosa, thus representing the
first spaceflight-induced regulator acting across bacterial species.
Nickerson's examination of the post-spaceflight alterations in
bacterial behaviour made use of microarray technology, which allows
analysis of gene expression for the entire 4.8 million base pairs
found in Salmonella's circular chromosome. Data revealed that 167
distinct genes and 73 proteins had been altered during growth under
microgravity conditions, including (but not limited to)
virulence-associated genes. Of the 167 genes undergoing up- or
down-regulation in response to spaceflight, one third were under the
control of the Hfq master regulator protein.
While Salmonella has been a pathogen of choice for a broad range
of spaceflight investigations, Nickerson stresses that her findings
have spaceflight and Earth-based implications. Her confidence is
based on her team's work showing that microgravity culture also
uniquely alters gene expression and pathogenesis-related responses
in other microorganisms.
Nickerson emphasizes that the ISS provides an unprecedented
opportunity to study the infection process under microgravity
conditions, enabling advances in our understanding of microbial gene
expression and accompanying host responses during infection in
fine-grained detail. This novel approach holds the potential to
identify new classes of genes and proteins associated with infection
and disease not possible using traditional experimental conditions
on Earth, where the force of gravity can mask certain cellular
responses.
Further, experiments aboard the ISS will permit the study of
microbial transitions and cellular responses to infection over a
prolonged time frame — an important advance not available during
shuttle-based experiments.
Microgravity research may provide an opportunity to identify
novel targets for vaccine development and the Nickerson team, in
collaboration with Roy Curtiss, director of the Biodesign
Institute's Center for Infectious Diseases and Vaccinology has been
working toward this goal. Based on previous findings, the scientists
hypothesized that results from microgravity experiments might be
used to facilitate vaccine development on Earth.
In a recent spaceflight experiment aboard space shuttle mission
STS-135, the team flew a genetically modified Salmonella-based anti-pneumoccal
vaccine that was developed in the Curtiss lab. By understanding the
effect of microgravity culture on the gene expression and
immunogenicity of the vaccine strain, their goal is to genetically
modify the strain back on Earth to enhance its ability to confer a
protective immune response against pneumococcal pneumonia.
"Recognizing that the spaceflight environment imparts a unique
signal capable of modifying Salmonella virulence, we will use this
same principle in an effort to enhance the protective immune
response of the recombinant attenuated Salmonella vaccine strain,"
Nickerson says.
Nickerson's space-based microgravity experiments are carried out
in conjunction with simultaneous Earth-based controls housed in the
same hardware as those in orbit, to compare the behaviour of
bacterial cells under normal Earth gravity. Additional information
is also provided using Earth-based cell cultures which are subjected
to a kind of simulated microgravity, produced by culturing cells in
a rotating wall vessel bioreactor (RWV), a device designed by NASA
engineers to replicate aspects of cell culture in the spaceflight
environment.
Back at ASU, RWV reactor experiments were conducted by Nickerson
and her team to help confirm that Hfq plays a central regulatory
role in the Salmonella response to spaceflight conditions. Nickerson
has also used this RWV technology to grow three dimensional (3-D)
cell culture models that mimic key aspects of the structure and
function of tissues in the body. These 3-D models are being used in
the Nickerson lab as human surrogates to provide novel insight into
the infectious disease process not obtainable by conventional
approaches and for drug/therapeutic testing and development for
treatment and prevention.
Nickerson also focuses research efforts on determining the entire
repertoire of environmental factors that may influence bacterial
response to spaceflight culture. For example, she found that the ion
concentration in the cell culture media played a key role in the
resulting effect of spaceflight on Salmonella virulence. Using the
RWV, she was able to identify specific salts that may be responsible
for this effect.
A new experiment will soon be flown on SpaceX Dragon slated for
the ISS later this year. Nicknamed PHOENIX, the project will mark
the first time a whole, living organism — in this case a nematode —
will be infected with a pathogen and simultaneously monitored in
real time during the infection process under microgravity
conditions.
This and future studies aboard ISS will almost certainly deepen
science's understanding of the molecular and cellular cues
underlying pathogenic virulence and open a new chapter in the
understanding of health and disease to benefit the general public.
"It is exciting to me that our work to discover how to keep
astronauts healthy during spaceflight may translate into novel ways
to prevent infectious diseases here on Earth," Nickerson says.
Source: The Biodesign Institute, Arizona State University